The Discovery of Sotorasib (AMG 510): First-in-Class Investigational Covalent Inhibitor of KRAS G12C
Join Brian Lanman of Amgen as he outlines the strategies used to overcome these challenges, the screening approaches employed to identify starting points for these efforts, and the optimization ...
The US Food and Drug Administration (FDA) has approved sotorasib (Lumakras, Amgen Inc.) with panitumumab (Vectibix, Amgen Inc.) for the treatment of certain adult patients with metastatic ...
Amgen has filed its groundbreaking KRAS inhibiting drug sotorasib with the FDA for a group of lung cancer patients with an aggressive form of the disease. The drug was the first targeted at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback